Type I IFNs predict positive results in the improvement of SARS-CoV-induced complications in the early phases (100), whereas a high level of IFN-γ at admission that persists in the following days can lead to poor outcomes in COVID-19 patients (87). Here, IFNG is linked to COVID-19.